

Auxesis Pharma Holding AB (publ) Org.no: 559196-6486

Cap Table & Investment Opportunity

The Opportunity

Auxesis Pharma develops differentiated pharmaceutical assets targeting high unmet medical needs in wound care and specialty dermatology.

- Late preclinical / early clinical specialty pharma strategy
- Focus on high-value, prescription-only therapeutic niches
- Scalable platform with global regulatory pathway (EU + US first)

Why Invest Now

- Clear regulatory pathway in major markets
- Strong IP strategy around formulation and indication expansion
- Capital-efficient development model
- Multiple partnering / licensing exit routes

Current Ownership Structure (Illustrative)

Shareholder Category	Ownership %
Founders & Management	65%
Early Investors	7%
Strategic / Industry	0%
ESOP / Incentive Pool	0%
Free Float / Other	28%

Financing Strategy

Current Round: VC Growth / Late Seed – Series A Bridge

Use of Funds: - Clinical development - Regulatory preparation EU / US - Manufacturing scale-up - Business development & partnering

Target Outcome

- Value inflection via clinical milestones
- Strategic licensing or M&A optionality
- Pathway toward specialty pharma commercial model

Investment Highlights

- Large global wound care and specialty dermatology market
- Strong differentiation vs existing topical therapies
- Platform potential beyond first product
- Experienced management and advisory network

Tier-1 VC Investment Story

The Problem

Chronic and complex wounds represent a massive and growing global healthcare burden.

- Rising incidence driven by aging population, diabetes, and trauma care improvements
- Limited pharmacological innovation in topical prescription wound therapy
- Current treatments often focus on symptom management rather than active biological modulation
- High healthcare system cost and poor patient quality of life

Result: Large unmet medical need with strong payer willingness for effective prescription therapies.

The Solution

Auxesis Pharma develops differentiated prescription topical pharmaceuticals for severe and complex wound environments.

Core Strategy:

- Novel pharmacological mechanism applied in topical wound treatment
- Designed for use in severe open wounds, burns, friction injuries and complex external skin damage
- Optimized for regulatory approval in EU and US first, with global expansion

Platform Potential:

- Indication expansion across multiple wound and dermatology segments
- Lifecycle management through formulation and indication strategy

Why Now

- Global wound care market expanding rapidly
- Regulatory pathways for specialty topical prescription drugs are well defined
- Increasing demand for cost-effective outpatient wound therapies
- Pharma partnering demand for de-risked specialty assets is strong

Traction & Value Inflection Plan

Near-Term Milestones

- Clinical development advancement
- Regulatory engagement EU / US
- Manufacturing scale readiness

Mid-Term Value Drivers

- Clinical proof-of-concept data
- Partnering / licensing discussions
- Indication expansion strategy

Business Model

- Asset-centric specialty pharma model
- Value creation through clinical de-risking
- Monetization via licensing, co-development, or strategic acquisition

Market Opportunity

- Large and growing global wound care market
- Premium pricing potential for prescription pharmacological solutions
- Strong reimbursement potential in EU and US specialty care settings

Competitive Advantage

- Pharmacology-driven wound treatment vs traditional passive topical care
- Strong IP strategy around formulation and use
- Capital-efficient development path
- Global regulatory-first strategy

Financing Strategy

Round: VC Growth / Late Seed – Series A Bridge

Use of Funds:

- Clinical development
- Regulatory preparation EU / US
- Manufacturing scale-up
- Business development and partnering

Exit Pathways

- Strategic licensing after clinical value inflection
- Acquisition by specialty pharma or wound care leader
- Multi-asset specialty pharma build-out optionality

The Vision

Build a global specialty pharma company focused on high-value topical prescription therapeutics for severe wound and dermatology indications.

Contact

Auxesis Pharma Holding AB (publ) Confidential – For Investor Discussion Only

